Tyler Van Buren
Stock Analyst at TD Cowen
(2.59)
# 1,291
Out of 4,667 analysts
59
Total ratings
38.71%
Success rate
6.35%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $45.56 | +64.64% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $18.54 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $20.28 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $36.72 | +63.42% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $11.05 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $16.68 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $745.09 | +61.06% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $45.20 | - | 1 | Jun 24, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | n/a | $20.34 | - | 1 | May 15, 2024 | |
| GILD Gilead Sciences | Maintains: Buy | $90 → $85 | $88.82 | -4.30% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $46.22 | -35.09% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.69 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $27.17 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $87.58 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.40 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.33 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $18.47 | +62.43% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.25 | - | 1 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.29 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.12 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.31 | +116.68% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.04 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.63 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.90 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.79 | +2,692.36% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $18.11 | +4,730.70% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $185 | $192.26 | -3.78% | 3 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $2.66 | +1,403.76% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $22.62 | +76.83% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.90 | +203.18% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.71 | +1,009.06% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $2.58 | +2,227.75% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $13.04 | +283.44% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.70 | +4,182.04% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $6.12 | +3,167.97% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.36 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.99 | - | 1 | Aug 4, 2017 |
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $45.56
Upside: +64.64%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $18.54
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $20.28
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $36.72
Upside: +63.42%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $11.05
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $16.68
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $745.09
Upside: +61.06%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $45.20
Upside: -
NewAmsterdam Pharma Company
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $20.34
Upside: -
Gilead Sciences
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $88.82
Upside: -4.30%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $46.22
Upside: -35.09%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.69
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.17
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $87.58
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $44.40
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.33
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $18.47
Upside: +62.43%
Feb 14, 2023
Initiates: Outperform
Price Target: n/a
Current: $54.25
Upside: -
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $23.29
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.12
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.31
Upside: +116.68%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.04
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.63
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.90
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.79
Upside: +2,692.36%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $18.11
Upside: +4,730.70%
Nov 6, 2020
Downgrades: Underweight
Price Target: $185
Current: $192.26
Upside: -3.78%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $2.66
Upside: +1,403.76%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $22.62
Upside: +76.83%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.90
Upside: +203.18%
Aug 4, 2020
Initiates: Overweight
Price Target: $30
Current: $2.71
Upside: +1,009.06%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $2.58
Upside: +2,227.75%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $13.04
Upside: +283.44%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.70
Upside: +4,182.04%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $6.12
Upside: +3,167.97%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $6.36
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.99
Upside: -